We recently published our article 10 Biotech Stocks to Buy Now as Novo Nordisk (NVO) Shakes Up the $100B Weight-Loss Market. In this piece, we take a closer look at Structure Therapeutics Inc. (NASDAQ:GPCR) to examine its latest developments, pipeline progress, and why it continues to draw attention from investors.

Novo Nordisk A/S (NYSE: NVO) helped transform obesity treatment from a relatively overlooked pharmaceutical category into one of Wall Street’s biggest healthcare stories. The success of GLP-1 weight-loss drugs proved that effective obesity medicines could generate blockbuster sales, attract millions of patients and reshape how doctors treat metabolic disease.

The opportunity is enormous. Obesity affects hundreds of millions of people worldwide and is associated with type 2 diabetes, cardiovascular disease, fatty-liver disease, sleep apnea and other serious health conditions. Yet only a small percentage of eligible patients currently receives modern prescription weight-loss treatments. That gap explains why analysts believe the global weight-loss drug market could eventually exceed $100 billion in annual sales.

The Next Winners May Offer More Than Weight Loss

The next phase of the obesity drug boom will not be based solely on which treatment produces the highest percentage of weight loss. Drugmakers are now developing oral GLP-1 pills, monthly injections, dual- and triple-hormone therapies, amylin-based medicines and treatments designed to preserve muscle while patients lose fat.

Here is an important piece of trivia: weight loss does not come entirely from body fat. Patients may also lose lean tissue, including muscle, which has pushed biotechnology companies to develop complementary treatments that improve the quality of weight loss. Others are working on easier dosing, fewer gastrointestinal side effects and medicines that may also improve liver, heart and metabolic health.

Oral obesity treatments could become especially disruptive. Many patients dislike needles, while pills may be easier to manufacture, distribute and use. A successful weight-loss pill would not necessarily need to outperform every injectable treatment. Convenience alone could allow it to capture a meaningful portion of the growing obesity treatment market.

Why Biotech Stocks Are Entering the Spotlight

Novo Nordisk A/S (NYSE: NVO) remains the company framing this story, but it is not included in the top 10 ranking. Instead, the countdown focuses on biotechnology stocks attempting to benefit from the market Novo Nordisk helped create.

Some of these companies are developing direct competitors to existing GLP-1 drugs. Others are pursuing different mechanisms, longer-lasting treatments or therapies that could eventually be prescribed alongside popular weight-loss medicines. Their success could lead to major commercial partnerships, acquisition interest or sharp valuation increases.

The risks are equally significant. Obesity drug trials are expensive, clinical results can disappoint and smaller biotechnology companies may need additional financing before reaching commercialization. Investors searching for the best biotech stocks to buy now should therefore examine clinical progress, cash reserves, safety data, competitive advantages and upcoming catalysts—not just ambitious weight-loss claims.

The following countdown identifies 10 biotechnology stocks positioned to participate in the next stage of the $100 billion weight-loss drug market, beginning with number 10 and moving toward the company offering the strongest combination of scientific promise, market opportunity and investment potential.

CHECK THIS OUT: Top 10 AI-Powered Healthcare Stocks That Can Make You Rich and Top 10 Healthcare Stocks That Could Turn a $1000 Investment Into Something Bigger.

Our Methodology

In order to arrive to our list of the 10 Biotech Stocks to Buy Now as Novo Nordisk (NVO) Shakes Up the $100B Weight-Loss Market, we examined the trending biotech stocks and based our ranking on each company’s clinical progress, treatment differentiation, market opportunity, financial position, upcoming catalysts, partnership potential and overall risk-reward profile within the rapidly growing obesity and metabolic-disease market.

10 Biotech Stocks to Buy Now as Novo Nordisk (NVO) Shakes Up the $100B Weight-Loss Market

8. Structure Therapeutics Inc. (NASDAQ:GPCR)

Structure Therapeutics Inc. (NASDAQ: GPCR) ranks eighth because aleniglipron has emerged as one of the strongest clinical-stage oral GLP-1 candidates outside Novo Nordisk A/S (NYSE: NVO) and Eli Lilly and Company (NYSE: LLY). Aleniglipron is a once-daily, nonpeptide small-molecule GLP-1 receptor agonist. Unlike peptide-based oral semaglutide, a small-molecule medicine could potentially be manufactured at a greater scale and taken with fewer restrictions involving meals or water, though its ultimate dosing instructions will depend on clinical and regulatory findings.

In March 2026, Structure Therapeutics Inc. (NASDAQ: GPCR) reported that aleniglipron produced placebo-adjusted mean weight loss of 16.3% at the 180-milligram dose and 16% at 240 milligrams after 44 weeks in the Phase 2 ACCESS II study. The company said participants had not yet reached a weight-loss plateau. In the ongoing extension study, participants receiving 120 milligrams recorded weight loss of as much as 16.2% after 56 weeks. Structure Therapeutics Inc. (NASDAQ: GPCR) planned to use an FDA end-of-Phase 2 meeting to finalize the design of a Phase 3 program scheduled to begin during the second half of 2026.

Chief Executive Officer Raymond Stevens previously said oral small-molecule GLP-1 treatments could “meaningfully expand access and options” for patients. That is the core investment case. Structure Therapeutics Inc. (NASDAQ: GPCR) does not have to defeat every injectable treatment to build a valuable franchise. It needs to show that aleniglipron provides competitive weight loss, acceptable gastrointestinal tolerability and convenient dosing at a manufacturable scale. The risks include treatment discontinuations, high required doses and the possibility that approved pills from Novo Nordisk A/S (NYSE: NVO) and Eli Lilly and Company (NYSE: LLY) establish dominant positions before aleniglipron reaches the market.

YOU MUST READ THIS: 10 Biotech Stocks That Could Turn Medicine Into Wall Street’s Next Gold Rush

Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.